This variant was genome-wide significant in previous GWAS studies for several cardiometabolic traits including Apolipoprotein A1 levels, waist-hip ratio, BMI, fat mass percentage, HDL-C, and T2D (Turcot et al., 2018; Van Der Harst and Verweij, 2018; Pulit et al., 2019; Richardson et al., 2020; Zhu et al., 2020). This evidence concerns the gene APOA1 and type 2 diabetes mellitus.